Navigation Links
Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontology's 94th Annual Meeting
Date:9/5/2008

VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that a poster entitled "Photodisinfection in the Treatment of Chronic Periodontitis" will be presented by Company representatives at the American Academy of Periodontology's (AAP) annual meeting. This year's AAP meeting is being held at the Washington State Convention and Trade Center in Seattle, Washington on September 6-9, 2008.

"We are pleased to have the opportunity to present photodisinfection to the U.S. periodontal community," said Carolyn Cross, Ondine's President and CEO. "This peer-reviewed poster highlights the positive results of the Company's Multi-Centre Trial using its Photodisinfection System. Periodontal pockets treated with photodisinfection (220mW laser plus photosensitizer) in addition to scaling and root planing (SRP) yielded statistically significant reductions in pocket depth (p=0.01) as well as increases in clinical attachment level (p=0.002) when compared to pockets treated only with SRP."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: http://www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for

the adequacy or accuracy of this release.


'/>"/>
SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ondine Biopharma Announces Second Quarter 2008 Financial Results
2. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
3. Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
4. MedQuist Announces Additions to Board of Directors
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Martek Announces Third Quarter 2008 Financial Results
7. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
8. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
9. American Oriental Bioengineering Announces Participation in September Investor Conferences
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Mindray Medical International Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... active R&D program for the development of future natural products ... unique research and development center in Israel ... Stockton has a variety of products ... is active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to ...
(Date:2/5/2016)... ATCC, the premier global biological materials resource ... and life science researchers that are working to address ... CDC website . --> CDC ... a single-stranded RNA virus of the Flaviviridae family, genus ... Chikungunya Viruses. Zika virus is transmitted to humans primarily ...
(Date:2/4/2016)... , ... February 04, 2016 , ... ... development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently ...
(Date:2/4/2016)... Beike Biotechnology, the Shenzhen ... ceremony in late 2015 to mark their successful combined ... --> --> The ... Cell Therapy" was hosted by the Shenzhen Cell Bank ... of Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):